Market Research Logo

Global Metastatic Cancer Treatment Market Forecast 2018-2026

Global Metastatic Cancer Treatment Market Forecast 2018-2026

KEY FINDINGS

The global metastatic cancer treatment market growth is being facilitated by the global rise in the prevalence of cancer, ongoing R&D in oncology and promised potential of alternative therapies. Over the projected years of 2018-2026, the market is expected to advance by exhibiting a CAGR of 7.13%.

MARKET INSIGHTS

The global metastatic cancer treatment market is segmented on the basis of therapeutic indication and products. The therapeutic indications include breast cancer, prostate cancer, lung cancer, melanoma, colorectal cancer and other therapeutic applications. The products for metastatic cancer treatment market is segmented into branded medicines and generic medicines. Market opportunities like the rise in the use of targeted drug therapies, increasing population with high risk of metastatic cancer and the development of cost-effective cancer drugs are expected over the projected years of 2018-2026. However, the market growth is being challenged by factors like the high price of cancer drugs, rigorous regulatory agenda and high capital investment.

REGIONAL INSIGHTS

Region-wise segmentation of the global metastatic cancer treatments market has been done into Asia-Pacific, Europe, North America and the rest of the world. By the end of the projected years, the North American market is expected to register the highest revenue share. The major contribution comes from the US and Canada market. However, the highest CAGR is expected from the Asia-Pacific market which is mainly being propelled by factors like changing lifestyles and increased exposure to cancer-causing mutagens. Major markets in this region are Singapore, Korea and Japan.

COMPETITIVE INSIGHTS

Some of the well-known market companies in the region are Abbvie Inc, Amgen, Inc, AstraZeneca Plc, Bayers Ag, Bristol-Myers Squibb, Celgene Corporation, Eli Lilly And Compan, F. Hoffmann-La Roche Ltd, Johnson & Johnson, Merck & Co. Inc, Novartis Ag, Pfizer Inc, Sanofi, and Takeda Pharmaceutical Company Limited.


1. Research Scope
1.1. Study Goals
1.2. Scope Of The Market Study
1.3. Who Will Find This Report Useful?
1.4. Study And Forecasting Years
2. Research Methodology
2.1. Sources Of Data
2.1.1. Secondary Data
2.1.2. Primary Data
2.2. Top Down Approach
2.3. Bottom-up Approach
2.4. Data Triangulation
3. Executive Summary
3.1. Market Summary
3.2. Key Findings
3.2.1. Breast Cancer Therapeutic Indication Is Majorly Used
3.2.2. Generic Medicines Are Anticipated To Grow At A Significant Rate
3.2.3. Melanoma Is The Most Prevailing Cancer
4. Market Determinants
4.1. Market Drivers
4.1.1. Rising Prevalence Of Cancer
4.1.2. Increasing Prevalence And Awareness About Metastatic Cancer
4.1.3. Growing R&D In The Field Of Oncology
4.1.4. Rising Aging Population
4.1.5. Advancements In Research & Development
4.1.6. Promised Potential Of Alternative Therapies
4.2. Market Restraints
4.2.1. Adverse Side Effects Of Chemotherapy
4.2.2. Reimbursement Issue
4.2.3. Poor Retention And Recruitment In Cancer Clinical Research Trials
4.3. Market Opportunities
4.3.1. Targeted Drug Therapies Are Rising
4.3.2. Increasing Population With High Risk Of Metastatic Cancer
4.3.3. Development Of Cost-effective Cancer Drugs
4.3.4. Strategic Approach Taken By The Cancer Drug Manufacturers
4.4. Market Challenges
4.4.1. High Price Tags Of Cancer Drugs
4.4.2. Rigorous Regulatory Agenda
4.4.3. High Capital Investment
5. Market Segmentation
5.1. Market By Therapeutic Indication 2018-2026
5.1.1. Breast Cancer
5.1.2. Prostate Cancer
5.1.3. Lung Cancer
5.1.4. Melanoma
5.1.5. Colorectal Cancer
5.1.6. Other Therapeutic Applications
5.2. Market By Products 2018-2026
5.2.1. Branded Medicines
5.2.2. Generic Medicines
6. Key Analytical
6.1. Porter’s Five Forces Analysis
6.1.1. Threat Of New Entrant
6.1.2. Threat Of Substitute
6.1.3. Bargaining Power Of Buyers
6.1.4. Bargaining Power Of Suppliers
6.1.5. Intensity Of Competitive Rivalry
6.2. Oncology Drugs Approvals By The Fda
6.3. Routes Of Metastasis
6.4. Regulatory Framework
6.4.1. Regulations In North America
6.4.2. Regulations In Europe
6.4.3. Regulations In Asia Pacific
6.4.4. Regulations In Latin America
6.4.5. Regulations In Middle East And Africa
6.5. Regulatory Designations
6.6. Patent Analysis
6.7. Pipeline Analysis
7. Geographical Segmentation
7.1. North America
7.1.1. The United States
7.1.2. Canada
7.2. Europe
7.2.1. The United Kingdom
7.2.2. Germany
7.2.3. France
7.2.4. Italy
7.2.5. Spain
7.2.6. Russia
7.2.7. Rest Of Europe
7.3. Asia Pacific
7.3.1. China
7.3.2. India
7.3.3. Japan
7.3.4. Australia
7.3.5. South Korea
7.3.6. Rest Of Apac
7.4. Rest Of World
7.4.1. Latin America
7.4.2. Middle East And Africa
8. Company Profiles
8.1. Competitive Landscape
8.1.1. Market Share Analysis
8.2. Abbvie Inc.
8.2.1. Company Profiles
8.2.2. Product Portfolio
8.2.3. Scot Analysis
8.2.4. Strategic Initiatives
8.3. Amgen, Inc.
8.3.1. Company Profiles
8.3.2. Product Portfolio
8.3.3. Scot Analysis
8.3.4. Strategic Initiatives
8.4. Astrazeneca Plc
8.4.1. Company Website
8.4.2. Product Portfolio
8.4.3. Scot Analysis
8.4.4. Strategic Initiatives
8.5. Bayers Ag
8.5.1. Company Overview
8.5.2. Product Portfolio
8.5.3. Scot Analysis
8.5.4. Strategic Initiatives
8.6. Bristol-myers Squibb
8.6.1. Company Profiles
8.6.2. Product Portfolio
8.6.3. Scot Analysis
8.6.4. Strategic Initiatives
8.7. Celgene Corporation
8.7.1. Company Overview
8.7.2. Product Portfolio
8.7.3. Scot Analysis
8.7.4. Strategic Initiatives
8.8. Eli Lilly And Company
8.8.1. Company Overview
8.8.2. Products Portfolio
8.8.3. Swot Analysis
8.8.4. Strategic Initiatives
8.9. F. Hoffmann-la Roche Ltd
8.9.1. Company Overview
8.9.2. Product Portfolio
8.9.3. Scot Analysis
8.9.4. Strategic Initiatives
8.10. Johnson & Johnson
8.10.1. Company Overview
8.10.2. Product Portfolio
8.10.3. Swot Analysis
8.10.4. Strategic Initiatives
8.11. Merck & Co., Inc.
8.11.1. Company Profiles
8.11.2. Product Portfolio
8.11.3. Scot Analysis
8.11.4. Strategic Initiatives
8.12. Novartis Ag
8.12.1. Company Overview
8.12.2. Product Portfolio
8.12.3. Scot Analysis
8.12.4. Strategic Initiatives
8.13. Pfizer, Inc.
8.13.1. Company Profiles
8.13.2. Product Portfolio
8.13.3. Scot Analysis
8.13.4. Strategic Initiatives
8.14. Sanofi
8.14.1. Company Overview
8.14.2. Products Portfolio
8.14.3. Swot Analysis
8.14.4. Strategic Initiatives
8.15. Takeda Pharmaceutical Company Limited
8.15.1. Company Overview
8.15.2. Products Portfolio
8.15.3. Swot Analysis
8.15.4. Strategic Initiatives
Table List
Table 1 Global Metastatic Cancer Treatment Market By Geography 2018-2026 ($ Million)
Table 2 R&D Expense By Major Pharmaceutical Companies In 2017
Table 3 Recent Approvals Of Metastatic Cancer Drugs
Table 4 Adverse Side Effects Of Metastatic Cancer Drugs
Table 5 Global Metastatic Cancer Treatment Market By Therapeutic Application 2018-2026 ($ Million)
Table 6 Company’s Manufacturing Drugs For Other Therapeutic Indications
Table 7 Global Metastatic Cancer Treatment Market By Products 2018-2026 ($ Million)
Table 8 Branded Drugs Used To Treat Metastatic Cancer
Table 9 Generic Drugs Used To Treat Metastatic Cancer
Table 10 Patent Products With The Expiry Date
Table 11 Patent Publications Related To Metastatic Breast Cancer 2017
Table 12 Patent Publications Related To Metastatic Prostate Cancer 2017
Table 13 Patent Publications Related To Metastatic Lung Cancer 2017
Table 14 Pipeline Analyses Of Metastatic Cancer Drugs
Table 15 Global Metastatic Cancer Treatment Market By Geography 2018-2026 ($ Million)
Table 16 North America Metastatic Cancer Treatment Market 2018-2026 ($ Million)
Table 17 Europe Metastatic Cancer Treatment Market 2018-2026 ($ Million)
Table 18 Asia Pacific Metastatic Cancer Treatment Market 2018-2026 ($ Million)
Table 19 State-wise Distribution Of Cancer In India
Table 20 Estimated Most Common Cancers Diagnosed In Australia 2017
Table 21 Rest Of World Metastatic Cancer Treatment Market 2018-2026 ($ Million)
Figures List
Figure 1 Global Metastatic Cancer Treatment Market 2018-2026 ($ Million)
Figure 2 Targeted Therapies For Different Cancer Types
Figure 3 Global Metastatic Cancer Treatment Market In Breast Cancer 2018-2026 ($ Million)
Figure 4 Symptoms Of Metastatic Breast Cancer
Figure 5 Global Metastatic Cancer Treatment Market In Prostate Cancer 2018-2026 ($ Million)
Figure 6 Global Metastatic Cancer Treatment Market In Lung Cancer 2018-2026 ($ Million)
Figure 7 Global Metastatic Cancer Treatment Market In Melanoma 2018-2026 ($ Million)
Figure 8 Global Metastatic Cancer Treatment Market In Colorectal Cancer 2018-2026 ($ Million)
Figure 9 Global Metastatic Cancer Treatment Market In Other Therapeutic Applications 2018-2026 ($ Million)
Figure 10 Global Metastatic Cancer Treatment Market In Branded Medicines 2018-2026 ($ Million)
Figure 11 Global Metastatic Cancer Treatment Market In Generic Medicines 2018-2026 ($ Million)
Figure 12 The United States Metastatic Cancer Treatment Market 2018-2026 ($ Million)
Figure 13 Canada Metastatic Cancer Treatment Market 2018-2026 ($ Million)
Figure 14 The United Kingdom Metastatic Cancer Treatment Market 2018-2026 ($ Million)
Figure 15 Germany Metastatic Cancer Treatment Market 2018-2026 ($ Million)
Figure 16 France Metastatic Cancer Treatment Market 2018-2026 ($ Million)
Figure 17 Italy Metastatic Cancer Treatment Market 2018-2026 ($ Million)
Figure 18 Spain Metastatic Cancer Treatment Market 2018-2026 ($ Million)
Figure 19 Russia Metastatic Cancer Treatment Market 2018-2026 ($ Million)
Figure 20 Rest Of Europe Metastatic Cancer Treatment Market 2018-2026 ($ Million)
Figure 21 China Metastatic Cancer Treatment Market 2018-2026 ($ Million)
Figure 22 India Pacific Metastatic Cancer Treatment Market 2018-2026 ($ Million)
Figure 23 Japan Metastatic Cancer Treatment Market 2018-2026 ($ Million)
Figure 24 Australia Metastatic Cancer Treatment Market 2018-2026 ($ Million)
Figure 25 South Korea Metastatic Cancer Treatment Market 2018-2026 ($ Million)
Figure 26 Rest Of Apac Metastatic Cancer Treatment Market 2018-2026 ($ Million)
Figure 27 Latin America Metastatic Cancer Treatment Market 2018-2026 ($ Million)
Figure 28 Middle East And Africa Metastatic Cancer Treatment Market 2018-2026 ($ Million)
Figure 29 Market Share Of Key Players In Metastatic Cancer 2017 (%)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report